iBio Q1 FY27 net loss widens 32% year over year to $7.55 million
IBIO•iBio’s net loss widened 32% year over year to $7.55 million in Q1 FY27, while revenue rose to $1.08 million. Cash, cash equivalents and investments in debt securities totaled $76.7 million at September 30, 2026.
1. Quarterly results and pipeline
iBio reported that research and development expenses climbed 87% year over year to $6.65 million, primarily due to increased spending on consultants and outside services. The company expects interim Phase 1 data for IBIO-600 in the first quarter of 2027 and plans first-in-human trials for IBIO-610 in the first half of 2027.
